Unusual Options Activity In Hims (HIMS)
4204 $HIMS MAR 14th 2025 43.00 CALLS BOUGHT@ 3 vs Open Interest of 103 for a total of $1261200 on the BULL side
Similar Posts
3/14/2024-Unusual Options Activity In NRG
NRG Energy, Inc. is an American energy company, headquartered in Houston, Texas. It was formerly the wholesale arm of Northern States Power Company, which became Xcel Energy, but became independent in 2000. NRG Energy is involved in energy generation and retail electricity.
11/21/2024 -Unusual Options Activity In Confluent (CFLT)
Confluent, Inc. is an American technology company headquartered in Mountain View, California.
1/18/2023-Unusual Options Activity In RKT
Rocket Companies, Inc., a fintech holding company, provides mortgage lending, title and settlement services, and other financial technology services in the United States and Canada. It operates through two segments, Direct to Consumer and Partner Network. The company’s solutions include Rocket Mortgage, a mortgage lender; Amrock that provides title insurance, property valuation, and settlement services; Rocket Homes, a home search platform and real estate agent referral network, which offers technology-enabled services to support the home buying and selling experience; Rocket Auto, a virtual marketplace where consumers can shop and compare vehicles of many makes and models from a wide network of dealers; and Rocket Loans, an online-based personal loans business.
10/2/2024-Unusual Options Activity In Enovix Corporation (ENVX)
Enovix Corporation is a company that designs, develops, and manufactures lithium-ion batteries for consumer and industrial equipment.
11/27/2023-Unusual Options Activity In CAVA
Cava Group, Inc. is a holding company, which engages in the operation of restaurants. It operates through the CAVA and Zoes Kitchen segments. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.
1/12/2023-Unusual Options Activity In AUPH
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
